The ubiquitin-proteasome pathway has been recognized as an important regulator in the hormonal response by estrogen receptor ER , but its impact on ER function is poorly characterized. In the current study, we investigated the role of the ubiquitin-proteasome pathway in regulating ER activity and identified regulatory sites within the activation function AF-1 domain that modulate ER ubiquitination and nuclear dynamics in a hormone-independent manner. Whereas both ER and ER were dependent on proteasome function for their maximal response to estrogen, they were regulated differently by proteasome inhibition in the absence of hormone, an effect shown to be dependent on their respective AF-1 domain. Given the role of AF-1 phosphorylation to regulate ER and ER activity, we found that sequential substitutions of specific serine residues contained in MAPK consensus sites conferred transcriptional activation of ER in a proteasome-dependent manner through reduced ubiquitination and enhanced accumulation of mutant receptors. Specifically, serines 94 and 106 within ER AF-1 domain were found to modulate sub-nuclear mobility of the receptor to transit between inactive clusters and a more mobile state in a proteasome-dependent manner. In addition, cellular levels of ER were regulated through these sites by facilitating the recruitment of the ubiquitin ligase E6-associated protein in a phosphorylation-dependent manner. These findings suggest a role for ER AF-1 in contributing to the activation-degradation cycling of the receptor through a functional clustering of phosphorylated serine residues that cooperate in generating signals to the ubiquitin-proteasome pathway.
Introduction
Estrogen plays a central role in reproductive physiology but also in pathological events such as breast and endometrium cancers. Regulation of target gene expression by estrogen is mediated upon its interaction with the estrogen receptors ER and ER , which belong to the nuclear hormone receptor family of ligand-activated transcription factors . Although ER shares similarities in terms of structure and response to hormone with ER , it is considered a strong predictive factor for endocrine therapy of reproductive cancers (1, 2) , whereas ER was shown to display anti-tumorigenic properties (3) (4) (5) .
The current model for transcriptional activation of estrogen responsive genes by ERs involves a conformational change upon ligand binding that favors interaction with their cognate estrogen response element (ERE) and combinatorial recruitment of transcriptional cofactor complexes that mediate chromatin reorganization and essential interactions with the basal transcription machinery (6, 7) . Increasing evidence indicates that upon activation of ER by estrogen, the recruitment of cofactors involved in chromatin remodeling, post-translational modifications and transcriptional activity among others, occurs in an ordered fashion, thereby integrating the response elicitated by estrogen upon inducible promoters (8) (9) (10) (11) . Such concerted recruitment between cofactors is predicted to limit transactivation by ER in response to changes in hormone levels.
Recent studies have integrated the ER -mediated response to estrogen with proteasomedirected degradation of the receptor, thus supporting a mean by which target cells can sustain or limit a hormonal response through a continuous receptor turnover. ER has been shown to be degraded through the 26S proteasome pathway in a ligand-dependent manner (12, 13) . Blocking proteasome activity with inhibitors such as MG132 impaired the ability of ER to mediate a 3 hormone-dependent transcriptional response and contributed to immobilize ER in an inactive state in the nucleus (14, 15) . Interestingly, components of the ubiquitin-proteasome system, such as the 19S proteasome regulatory subunit Trip1/SUG1 (16, 17) and the E3 ubiquitin ligases MDM2 (18) and E6-AP (19) , have been shown to enhance the transcriptional activity of several nuclear receptors including ER . Moreover, these components were shown to cyclically reside with ER on the pS2 responsive promoter in both a ligand-dependent and -independent manner, an effect abolished by MG132 resulting in the inhibition of pS2 gene transcription (10, 11) . These findings thus suggest that the proteasome-mediated degradation process is closely related to ER transcriptional competence.
Ubiquination of ER has been demonstrated to vary upon the presence of hormone or antiestrogens, and the extent of ubiquitination was shown to correlate with receptor degradation, suggesting that ligand-dependent conformational changes can modulate ER ubiquitination (13, 20) . Interestingly, unliganded ER was also demonstrated to be ubiquitinated (10, 13) , therefore providing evidence that mechanisms other than ligand binding may dictate ubiquitination. As such, other signaling events have also been proposed to regulate ER and ER activity. Studies have reported that the ability of epidermal growth factor EGF to activate ER involved a MAPK-mediated phosphorylation of serine-118 within ER AF-1 domain (21, 22) . Such activation of ER by phosphorylation was proposed to involve coactivator recruitment at the AF-1 domain of ER (23) . Similarly, we demonstrated that ER activity is also modulated by growth factor signaling through MAPK-directed phosphorylation of AF-1 (24). Such activation was found to involve a favored recruitment of coactivators SRC-1 and CBP upon phosphorylation of ER AF-1 serines 106 and 124 (25, 26) . However, the role of AF-1 in mediating ER response to non-hormonal stimuli remains poorly defined and although both ER 4 and ER are regulated by growth factors, differences in terms of respective cofactor recruitment and AF-1 activity have been observed (27, 28) .
In the present study, we investigated the function of the ubiquitin-proteasome pathway in modulating the AF-1 dependent transcriptional response of ER . We identified specific MAPK sites within ER AF-1 domain that regulate ER activity in a proteasome-dependent manner by modulating receptor ubiquitination, sub-nuclear mobility, and recruitment of E6-AP ubiquitin ligase. Our results demonstrate a role for the AF-1 domain to regulate the activation-degradation process of ER , thereby integrating its response to changes in kinase-activated pathways.
Results

ER and ER -mediated transcription are dependent upon proteasome function
In order to assess the role of the proteasome pathway of degradation on ER and ER transcriptional function, we first tested the effects of proteasome inhibition on the hormonal response of both receptors in human embryonic kidney 293 cells transfected with either ER or ER and the estrogen-responsive luciferase reporter EREbLuc construct. As also reported (14) , ER mediated transcriptional activation in the presence of estrogen was nearly abolished by MG132, an inhibitor of the 26S proteasome (Fig.1A) . The hormonal response of ER was also decreased using clasto-lactacystin, an irreversible proteasome inhibitor. Under the same conditions, we also observed that ER was subjected to a similar dependence on the proteasome pathway in its response to estrogen (Fig.1A) . These results indicate that maximal activation of ER and ER by estrogen requires proteasome function.
In order to test whether the activity of ER and ER in absence of hormone was also dependent upon proteasome function, 293 cells were treated with increasing doses of MG132 in absence of estrogen and ER-driven luciferase activity was measured. We found that whereas basal ER -mediated transcription was enhanced by MG132, similar doses of inhibitor had no significant effect on ER -dependent activity (Fig.1B) . To ensure that this difference in response of ER and ER to MG132 is not related to variations in their cellular content, both ER and ER are shown to accumulate in cells treated with MG132 compared to untreated cells, consistent with the inhibition of their degradation (Fig.1C ).
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The AF-1 domain affects differently ER and ER activity during proteasome inhibition Given the apparent difference in the requirement of the proteasome function involved in ligand-independent activity of ER and ER , we determined the relative contribution of each receptor AF-1 domain on ER activity in response to proteasome inhibition. Truncated forms of ER and ER were transfected and tested for their activity in absence of hormone. We observed that for ER , removal of the N-terminal AB domain (CDEF construct in Fig.2A ) did not greatly alter ER response to proteasome inhibition, whereas removal of the AB region of ER (CDEF construct) resulted in a marked activation in the presence of MG132. These results suggest that each respective AF-1 domain may regulate differently the activity of ER and ER in a proteasome-dependent manner. In support of such different role, cells expressing ABC construct showed a stronger activation in response to proteasome inhibition compared to cells expressing ABC ( Fig.2A) . This apparent diverse contribution of each AF-1 was also transposable, as demonstrated with the use of chimeric forms of ER in which the AB region for each receptor was fused to the CDEF portion of the other, thus creating an ER and ER fusion chimeras. As such, the addition of the AB region to CDEF did not significantly modify the activation levels observed for CDEF with MG132 or clasto-lactacystin (compare ER with CDEF in Fig.2A ), whereas fusion of AB to CDEF decreased the activation of CDEF by both inhibitors, resulting in an activation profile more closely related to ER than to ER .
These results demonstrate a role for the AF-1 domain in regulating ER transcriptional activity which is dependent upon proteasome function, and further suggest that regulatory signals are contained within this region to mediate receptor turnover and activity. Consistent with these 7 observations, the N-terminal ABC construct was shown to strongly accumulate when expressed in cells treated with MG132 compared to untreated cells as determined by Western analysis, suggesting that this region itself is subjected to proteasome-dependent degradation (Fig.2B ).
Under similar conditions, ABC also accumulated but to a lesser extent than ABC , whereas CDEF and CDEF levels remained respectively unaffected or slightly increased upon MG132 treatment.
Contribution of MAPK consensus sites in proteasome-regulated transcription by ER .
Our earlier studies have determined that phosphorylation of AF-1 in response to MAPK in the presence of MG132, while the Ser-69 substitution had no effect. Higher levels of activation were observed with the Ser-106 variant, reaching a near 4-fold increase. Interestingly, when Ser-94 was also substituted, thus creating a S94,106A double mutant, the increase in activity by proteasome inhibition was even stronger with a 7-fold increase compared to each respective single mutant. Other multiple variants containing the S106A mutation, such as the S106,124A and S94,106,124A variants, were also induced, although to a lesser extent than the 8 S94,106A mutant, in response to proteasome inhibition (Fig.3A) . To ensure whether the apparent deregulation to proteasome inhibition in ER activity upon serine modifications resulted from the AF-1 domain itself, as suggested from the results presented in Fig.2A , we performed luciferase assay with corresponding serine mutants in which the DEF region of ER was removed. A comparable activation profile of the ABC constructs carrying successive substitutions of Ser-94, -106 and -124, was obtained (Fig.3B ). In addition, removal of the DEF region conferred an even greater transcriptional potential to the S94,106A mutant in response to proteasome inhibition, reaching a 14-fold increase, compared to its corresponding full-length version (Figs.3A and B). A role for the AF-2 function in regulating transcription in a manner dependent on proteasome activity has already been described for ER (13, 14) , and our results support a similar role for ER as well. However, coordinate removal of specific serine residues within ER AF-1 domain confers transcriptional activation when proteasome function is disrupted, raising the possibility that AF-1 regulatory sites participate in ER degradation by the proteasome.
To test how the AF-1 serine substitutions may affect the steady-state levels of ER , we performed Western analysis on cells expressing wild-type and mutated ER in response to proteasome inhibition. Whereas wild-type ER levels were markedly increased in cells treated with MG132, the ER variants carrying the Ser-94 and/or Ser-106 substitutions, in the context of full-lenght or DEF-truncated receptor, were less prone to accumulate ( Fig.3C and D) . Therefore, the changes in cellular levels of the S94,106A and S94,106,124A mutants did not account for the increase in their transcriptionnal activity following inhibition of proteasome function, but rather indicate an inverse relationship between receptor activity and cellular content. Such correlation 9 has also been described for ER in response to hormone and shown to be required to achieve maximal receptor activation (13, 14) .
Contribution of AF-1 serine residues in ER stability and ubiquitination
Because we found that the S94,106A mutation rendered ER less prone to accumulate upon the presence of MG132, we performed a cycloheximide chase to evaluate the impact of the mutation on ER protein turnover. As shown in Fig.4A and B, the half-life of ER increased from ~8h to approximately 12h by disruption of Ser-94 and -106, indicating that at least these residues are involved in ER degradation. Ubiquitination is the post-translational process commonly used to tag and direct proteins to degradation by the 26S proteasome, and the pattern and the extent to which a protein is ubiquitinated determine its rate of degradation (29). We analyzed whether ER was ubiquitinated in absence of ligand, and how the S94,106A
substitution may affect ER ubiquitination in vivo. By expressing ER in cells with taggedubiquitin, we observed several ubiquitinated forms of ER , which accumulated in the presence of MG132 (Fig.4C) . Interestingly, reduced levels of ubiquitination were observed in cells expressing the S94,106A mutant, and treatment with MG132 had moderate effect on receptor ubiquitination, when compared to wild-type ER . The apparent lower levels of ubiquitination of the S94,106A mutant suggest it has a reduced ability to be targeted by ubiquitination, which may then result in enhanced stability and transcriptional activity. This indicates that specific residues within the AF-1 of ER modulate receptor ubiquitination in absence of ligand and therefore contribute to ER degradation by the proteasome.
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AF-1 modifications affect the nuclear-cytoplasmic distribution of ER
Receptor redistribution between nuclear and cytoplasmic compartments has been described for many nuclear receptors in response to agonists and antagonists, and at least for ER , such response was shown to affect receptor proteolysis (13, 20, 30) . In order to test whether AF-1 substitutions may alter the nuclear-cytoplasmic distribution of ER in a proteasome-dependent manner, we determined the relative protein levels of ER compared to the S94,106A mutant in each cellular compartment. Both nuclear and cytoplasmic fractions were isolated and validated for the presence of selective markers PARP and GAPDH, respectively (Fig.5A ). We found higher levels of the S94,106A variant in both nuclear and cytoplasmic fractions of untreated cells, when compared to wild-type ER ( Fig.5B ), supporting a less propensity of the mutant to be ubiquitinated and a prolonged half-life in conditions in which proteasome function is not impaired. In addition, the levels of nuclear S94,106A mutant were not significantly changed upon proteasome inhibition, while ER accumulated in the same conditions, suggesting that serines 94 and 106 contribute to modulate the nuclear-cytoplasmic distribution of ER in a proteasome-dependent manner (Fig.5B ).
Sub-nuclear trafficking of ER is dependent on AF-1 modifications and proteasome function
Earlier studies using fluorescence recovery after photobleaching or FRAP, have revealed the dynamic nature of steroid receptor movement within the nucleus and their association with active chromatin templates to engage transcriptional regulation (15, 31) . Based on FRAP studies, the intranuclear mobility of ER was found to be affected differently depending upon the addition of agonist or antagonist, indicating that ER may associate to respectively 11 transcriptionally active domains within the nucleus or immobilized to inactive clusters referred to as the nuclear matrix (10, 15, 32) . Inhibition of proteasome activity was also shown to immobilize ER to components of the nuclear matrix in treated cells (20, 33) . We therefore evaluated how inhibiting proteasome activity may affect the mobility of ER and on the possible role of disrupting AF-1 activity under these conditions. FRAP analysis was performed on cells transfected with a YFP fusion of ER , which was initially validated for correct size by Western blot and for activity by luciferase assay (data not shown). In absence of ligand, ER was found highly mobile, reaching equilibrium in the bleached region within seconds, with a half-maximal recovery time (t½) of 1.7 ± 0.2 sec (n = 12 nuclei) ( resulted in a profound immobilization of unliganded ER , such that the half-recovery time could not be estimated (t½ > 300 sec, Fig.5D ). Such proteasome-dependent immobilization has been suggested to result from the clustering and association to non-chromatin templates, which is consistent with the transcriptional activity we measured for ER in the presence of MG132.
Remarkably, removal of Ser-94 and -106 in ER resulted in a more mobile receptor in the presence of MG132 (t½ = 39 ± 5 sec; n = 15 nuclei), suggesting that these sites were important to facilitate ER to immobilize in response to proteasome inhibition (Fig.5D ). This behavior was also observed with the S94,106,124A mutant (t½ ~ 60 sec; data not shown). These results indicate that disruption of ER AF-1 activity may allow the receptor to escape from associating with inactive clusters during proteasome inactivation, and therefore become available for 12 transcriptional regulation. Consistent with these findings is the potent activation we observed for the S94,106A and S94,106,124A mutants by MG132 ( Fig.3A and B) .
The E6-AP ubiquitin ligase regulates ER degradation
E6-AP, an E3 ubiquitin-protein ligase proposed to mediate substrate specificity of the ubiquitin-proteasome degradation system (34), has been shown to participate in the degradation of ER in response to estrogen (19, 35, 36) . We tested whether E6-AP could also regulate the Under the same conditions, the S94,106A mutant was less affected. These effects were dependent on the E3 ligase activity of E6-AP, as suggested with the use of a ligase defective C833A mutant, which did not decrease ER levels (Fig.6B ).
The expression of E6-AP also reduced the half-life of ER in cells to approximately 4h, compared to ~8h in cells not transfected with E6-AP, whereas the turnover rate of the S94,106A mutant was less affected with a half-life of ~11h (compare Fig.6C ; left panel and Fig.4B ).
Activation of Erk in cells expressing ER also contribute to accelerate its degradation with a half-life of ~2h, an effect shown to be highly dependent upon the integrity of Ser-94 and -106
( Fig.6C ; right panel).
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The E6-AP ubiquitin ligase is recruited to ER in a phosphorylation-dependent manner through serines 94 and 106
Based on the ability of E6-AP to regulate ER turnover, we then addressed whether E6-AP can be recruited to ER using co-immunoprecipitation assays. Fig.7A shows that E6-AP was detected in the ER immunoprecipitates, indicating that both proteins can interact. However, the extent by which E6-AP can be recruited to ER was severely diminished upon disruption of Ser-94 and -106, suggesting that these sites behave as important determinants in the interaction.
More interestingly, the recruitment of E6-AP to ER was more pronounced in response to MAPK activation as shown in cells transfected with Mek1 and Erk compared to control cells (Fig.7B ). The S94,106A mutation severely impaired the effect of MAPK activation on the ability of ER to efficiently recruit E6-AP (Fig.7B) . These results suggest that the interaction of ER with E6-AP is regulated in a phosphorylation-dependent manner and involves Ser-94 and -106 of ER AF-1 domain.
14 Discussion
In this study, we identify an important and unrecognized function of the AF-1 domain in targeting ER to the degradation process mediated by the ubiquitin-proteasome system. The current model of ER degradation has mostly been described for ER in response to estrogen.
Studies using proteasome inhibitors have shown that the hormonal activation of ER was dependent upon the ubiquitin-proteasome pathway, therefore establishing a correlation between receptor degradation and activity, an observation also made for other nuclear receptors (12, 37) .
Similarly to ER , we report that the response of ER to estrogen also required the proteasome function to achieve optimal receptor activation. However, in absence of hormone, while both
ERs accumulated in cells treated for proteasome inhibition, the role of the proteasome in maintaining basal ER activity seemed to be different between the two receptor isoforms. Using truncated versions of ER and ER , we observed that such difference was dependent on the Nterminal region of each receptor, and that at least for ER , the N-terminal domain was itself regulated by the proteasome in both its cellular content and activity. Using a similar deletion within ER , it was demonstrated that ER N-terminal region was stabilized during proteasome inhibition but this effect could not be correlated with its transcriptional activity (14) . The significance of an apparent correlation between AF-1 activity and ER degradation is not completely understood, but it becomes clear that AF-1 activity could impact ER degradation and that this may occur in an isoform-dependent manner. Consistent with this, whereas the AF-1 region was shown to regulate the ligand-induced degradation of ER (38) These results therefore suggest that disruption of ER AF-1 activity may allow the receptor to escape from associating to inactive clusters during proteasome inhibition, and to become or remain available for transcriptional regulation. Consistent with this hypothesis is the potent activation we observed for the S94,106A mutant in the presence of MG132 and its reduced ubiquitination, indicating that the absence of these residues may lead to a deregulated ER which would be less prone to proteasome-mediated degradation. The apparent inability of the AF-1 mutants to behave such as the wild-type ER and remained clustered and immobilized during proteasome inhibition raised the interesting question as to whether AF-1 phosphorylation could signal ER to transit from active to inactive chromatin compartments. Since these clustered residues are known to be targeted by MAPK and therefore participate in the response of ER to growth factor signaling (2,25), it would be expected that such intranuclear behavior may be shared with other nuclear receptors described to also be regulated by kinase-activated pathways.
In that respect, we recently reported that activation of Akt modulated the intranuclear behavior and activity of ER , and its segregation with coactivator CBP through a conserved Akt site shared with other nuclear receptors (48).
The transcriptional deregulation of ER characterized by its enhanced activity during proteasome inhibition upon AF-1 disruption was rather intriguing and suggested a mechanism by which the AF-1 may participate in restraining or at least maintaining an adequate and regulated response of ER to cellular pathways involving MAPK activation. In an attempt to partly 18 elucidate such mechanism, the E6-AP ubiquitin ligase was found to be favorably recruited to ER in response to signals that promote ER phosphorylation. Notably, this interaction was strongly dependent upon the presence of Ser-94 and -106 which resulted in a more rapid degradation of ER in response to Erk activation. This suggests that phosphorylation at these sites regulates ER turnover through the functional recruitment of components of the proteasome degradation pathway. Many studies, mostly involving ER , have depicted a role for estrogen to modulate ER cellular levels through the ubiquitin-proteasome pathway, thereby providing a functional link between receptor turnover and activity. As such, several proteins that exhibit E3
ubiquitin-protein ligase activity, such as Mdm2 (18), CHIP (49,50), BRCA1 (51) and E6-AP (19) , have been shown to modulate the hormonal response of ER . In that respect, E6-AP was described as a dual-function protein that associates with ER to promote its degradation and coactivation by estrogen (19, 35, 36) . This study extends the role of E6-AP to regulate ER degradation through the proteasome pathway and, with the increased ability of ER to recruit E6-AP compared to the S94,106A mutant in response to Erk activation, it further identifies a novel function for serines 94 and 106 in maintaining sub-optimal ER levels. These observations suggest a role for the AF-1 domain to provide the necessary signals through phosphorylation of critical residues in order to recruit E6-AP and dictate ER turnover under ligand-independent mechanisms. It was recently reported that the estrogen-dependent proteolysis of ER was mediated through the recruitment of the E3 ligase CHIP to the N-terminal region of ER (46).
This raises the interesting possibility that a selective recruitment of specific E3 ligases may be dependent on the upcoming activation signal, whether it is hormonal or kinase-derived, to ER .
Based on studies which have identified various E3 ligases associated with ER degradation by estrogen Mdm2 (18, 19, (49) (50) (51) , it is likely that the cellular context and/or other structural 19 determinants, such as phosphorylation, might dictate selectivity in recruiting components of the proteasome pathway. Consistent with this, the estrogen-induced recruitment of Mdm2 and E6-AP to ER -responsive genes was shown to be dependent on the presence of S118, a phosphorylation site within ER AF-1 (38) , and on the context of ER -targeted promoters (52).
The study presented here on the role of selective serine residues within ER AF-1 domain that participate in E6-AP recruitment and ubiquitination, combined with the apparent overlap of these sites to mediate coactivator recruitment in response to growth factor signaling pathways and subjected to SDS-PAGE and immunoblotting as described above using anti-HA antibody.
Co-immunoprecipitation analysis was performed to detect ER /E6-AP interaction in cells 22 transfected with wt or mutated ER (myc-tagged) in the presence of HA-tagged E6-AP.
Immunoprecipitation of ER was performed as above with an anti-myc antibody (9E10), except that salt concentration was raised to 0.7M and no SDS was added in the lysis buffer. The anti-HA antibody (12CA5) was used for immunoblotting.
Cycloheximide chase. 293 cells were transiently transfected with plasmids expressing HAtagged wild-type or S94,106AER in absence or presence of E6-AP or Mek1/Erk2 plasmids. At 12 hours after transfection, cycloheximide (Sigma) was added at a concentration of 50µM and cells were lysed for Western blot analysis at the indicated time points. Each signal intensity derived from two separate experiments was quantitated using an image analyzer (Alpha Innotech, San Leandro, CA) and expressed relative to -actin levels.
Preparation of nuclear and cytoplasmic extracts. To prepare nuclear and cytoplasmic extracts, cells were pelleted by centrifugation, resuspended in hypotonic buffer containing 10mM Hepes, pH7.9, 1.5mM MgCl 2 , 10mM KCl, 0.5mM DTT, 1mM sodium orthovanadate, 1mM sodium fluoride, 0.5mM PMSF and protease inhibitors, and lysed by three freeze-thaw cycles. Nuclei were separated from the cytosolic fraction by centrifugation at 12000g for 5min at 4°C. The nuclear pellet was resuspended in the same hypotonic buffer except that salt concentration was raised to 420mM KCl and 25% (v/v) glycerol was added. Equivalent amounts of cytoplasmic and nuclear fractions were then subjected to SDS-PAGE for Western analysis. The content of selective markers for nuclear (anti-PARP; Santa Cruz Biotech) and cytoplasmic (anti-GAPDH; Santa Cruz Biotech) compartments was tested by immunoblotting to ensure for the qualitative purity of the prepared fractions.
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Fluorescence recovery after photobleaching (FRAP). FRAP analysis was carried out on live 293 cells transfected with YFP fusions of wild-type or S94,106A mutant of ER . Cells were grown on chambered slides (LabTek) in phenol red-free DMEM containing 5% charcoal dextran-treated serum, and transfected by the calcium-phosphate procedure as descrived above.
FRAP experiments were performed on a Zeiss LSM510 confocal microscope equipped with an
Argon 514nm laser and a 530nm LP filter. A single z-section image of whole cell nuclei was captured before the bleach and at the indicated time points after. The bleached regions correspond to <10% of total nucleus using 100% laser intensity while scanned images were taken at 0.1% with an open pinhole and a numerical aperture of 0.8 to ensure that diffusion in the z dimension is avoided. Fluorescence intensities were analyzed using Zeiss Physiology sofware 3.2 and averaged from at least 10 nuclei. by Western analysis using an anti HA antibody. ER was also monitored in each sample using an ER antibody. B-E6-AP is recruited in a phosphorylation-dependent manner involving Ser-94
and -106. Coimmunoprecipitation assay as described in (A) except that Mek1/Erk plasmids were used in transfection to promote Erk activation and no MG132 was added to cells. 
